AADI (Aadi Bioscience) Inventory Turnover : 0.14 (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Aadi Bioscience Inventory Turnover?

Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. Aadi Bioscience's Cost of Goods Sold for the three months ended in Sep. 2024 was $0.80 Mil. Aadi Bioscience's Average Total Inventories for the quarter that ended in Sep. 2024 was $5.78 Mil. Aadi Bioscience's Inventory Turnover for the quarter that ended in Sep. 2024 was 0.14.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Aadi Bioscience's Days Inventory for the three months ended in Sep. 2024 was 656.34.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Aadi Bioscience's Inventory-to-Revenue for the quarter that ended in Sep. 2024 was 0.80.

Aadi Bioscience Inventory Turnover Historical Data

The historical data trend for Aadi Bioscience's Inventory Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aadi Bioscience Inventory Turnover Chart

Aadi Bioscience Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Inventory Turnover

0.72

0.68

Aadi Bioscience Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Inventory Turnover	Get a 7-Day Free Trial												0.20	0.18	0.11	0.13	0.14

Aadi Bioscience Inventory Turnover Calculation

Aadi Bioscience's Inventory Turnover for the fiscal year that ended in Dec. 2023 is calculated as

	Inventory Turnover (A: Dec. 2023 )
=	Cost of Goods Sold	/	Average Total Inventories
=	Cost of Goods Sold (A: Dec. 2023 )	/ (	(Total Inventories (A: Dec. 2022 )	+	Total Inventories (A: Dec. 2023 ))	/	count )
=	2.809	/ (	(1.861	+	6.427)	/	2 )
=	2.809	/	4.144
=	0.68

Aadi Bioscience's Inventory Turnover for the quarter that ended in Sep. 2024 is calculated as

	Inventory Turnover (Q: Sep. 2024 )
=	Cost of Goods Sold	/	Average Total Inventories
=	Cost of Goods Sold (Q: Sep. 2024 )	/ (	(Total Inventories (Q: Jun. 2024 )	+	Total Inventories (Q: Sep. 2024 ))	/	count )
=	0.804	/ (	(6.098	+	5.468)	/	2 )
=	0.804	/	5.783
=	0.14

Aadi Bioscience (NAS:AADI) Inventory Turnover Explanation

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Aadi Bioscience's Days Inventory for the three months ended in Sep. 2024 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Sep. 2024 )	/	Cost of Goods Sold (Q: Sep. 2024 )	*	Days in Period
	=	5.783	/	0.804	*	365 / 4
	=	656.34

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Aadi Bioscience's Inventory to Revenue for the quarter that ended in Sep. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Sep. 2024 )	/	Revenue (Q: Sep. 2024 )
	=	5.783	/	7.212
	=	0.80

Be Aware

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.

Aadi Bioscience Inventory Turnover Related Terms

Thank you for viewing the detailed overview of Aadi Bioscience's Inventory Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

Aadi Bioscience Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aadi Bioscience Inc (NAS:AADI) » Definitions » Inventory Turnover

Comparable Companies

Traded in Other Exchanges

N/A

Address

17383 Sunset Boulevard, Suite A250, Pacific Palisades, CA, USA, 90272

Website

https://www.aadibio.com

Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.

Executives

David James Lennon	director, officer: Chief Executive Officer	C/O AADI BIOSCIENCE, INC., 17383 SUNSET BLVD, SUITE A250, PACIFIC PALISADES CA 90272
Neil Desai	director, officer: See Remarks	C/O AADI BIOSCIENCE, INC., 17383 SUNSET BLVD., SUITE A250, PACIFIC PALISADES CA 90272
Mohammad Hirmand	director	C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Scott M. Giacobello	officer: Chief Financial Officer	SOVEREIGN HOUSE, VISION PARK, HISTON, CAMBRIDGE X0 CB24 9BZ
Lorettta M Itri	officer: Chief Medical Officer
Brendan Delaney	officer: Chief Operating Officer	300 THE AMERICAN WAY, MORRIS PLAINS NJ 07950
Emma Reeve	director	C/O PAREXEL INTERNATIONAL CORPORATION, 195 WEST STREET, WALTHAM MA 02451
Karin M. Hehenberger	director	C/O CORONADO BIOSCIENCES, INC., 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON CO 01803
Richard E Maroun	director	C/O AADI BIOSCIENCE, INC., 17383 SUNSET BLVD., SUITE A250, PACIFIC PALISADES CA 90272
Caley Castelein	director	THOM. WEISEL HEALTHCARE VENTURES, ONE MONTGOMERY STREET, SAN FRANCISCO CA 94104
Lance E Thibault	officer: Chief Financial Officer
Behzad Aghazadeh	director, other: See Remarks	C/O AVORO CAPITAL ADVISORS LLC, 110 GREENE STREET, SUITE 800, NEW YORK NY 10012
Venbio Select Advisor Llc	director, other: See Remarks	110 GREENE STREET, SUITE 800, NEW YORK NY 10012
Anupam Dalal	director	88 KEARNY STREET, SUITE 1800, SAN FRANCISCO CA 94108
Avoro Ventures Llc	director, other: See Remarks	110 GREEN STREET, SUITE 800, NEW YORK NY 10012